20-023 - Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
Status: open| S1900C - A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) |
Treatment for Lung Cancer
Description
This is an investigational study of two drugs (talazoparib and avelumab) used in combination to treat a type of lung cancer (non-squamous non-small cell lung cancer [NSCLC]) in patients whose disease has progressed. The goal of this study is to target a mutation that can occur within the cancer cells of some non-squamous NSCLC patients.
Sponsors
This trial is sponsored by National Cancer Institute (NCI).Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
![Sachin Pai]()
View ProfileSachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
Sub Investigators
![Moh'd Khushman]()
View ProfileMoh'd Khushman, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
This link will open in a new tab or window.